Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models Yong S. ChangJalila AdnaneScott Wilhelm Original Article 08 December 2006 Pages: 561 - 574
Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma Takenori NiiokaTsukasa UnoTomonori Tateishi Original Article 16 August 2006 Pages: 575 - 580
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer Tomasz M. BeerMilind M. JavleDonald L. Trump Original Article 26 October 2006 Pages: 581 - 587
In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng Wei WangYuqing ZhaoRuiwen Zhang Original Article 22 August 2006 Pages: 589 - 601
Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster R. F. C. LeitãoR. A. RibeiroG. A. C. Brito Original Article 31 August 2006 Pages: 603 - 612
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study Daniele SantiniBruno VincenziGiuseppe Tonini Original Article 31 August 2006 Pages: 613 - 620
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter Rosalyn JuergensJulie BrahmerDavid Ettinger Original Article 26 August 2006 Pages: 621 - 629
A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer Takuo HaraKenji OmuraJunichi Sakamoto Original Article 22 August 2006 Pages: 631 - 636
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Emilio BajettaLaura CatenaRoberto Bajetta Original Article 26 August 2006 Pages: 637 - 642
Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis Marcos Venício Alves LimaFrancisco Valdeci FerreiraRonaldo Albuquerque Ribeiro Original Article 01 September 2006 Pages: 643 - 650
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models Jianping ChenMelissa SmithBrian Higgins Original Article 26 August 2006 Pages: 651 - 659
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours Johnson J. LiuLai-Ming ChingMark J. McKeage Original Article 31 August 2006 Pages: 661 - 669
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration Alan P. BrownTage C. G. CarlsonMichael J. Graziano Original Article 31 August 2006 Pages: 671 - 679
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial M. B. JamesonB. C. Baguleyon behalf of the Cancer Research (UK) Phase I/II Trials Committee Clinical Trial Report 23 September 2006 Pages: 681 - 687
Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors M. CamponeN. IsambertP. Fumoleau Clinical Trial Report 10 October 2006 Pages: 689 - 695
Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas Bih Fang PanJ. Arly Nelson Short Communication 29 September 2006 Pages: 697 - 702
